Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBritish American Tobacco Regulatory News (BATS)

Share Price Information for British American Tobacco (BATS)

Share Price is delayed by 15 minutes
Get Live Data
4,404.00    84.00 (1.94%)
Bid:
4,423.00
Ask:
4,425.00
Spread: 2.00 (0.045%)
Market Cap: £95.19b
BATS Live PriceLast checked at - London Stock Exchange

Intraday British American Tobacco Share Chart

Response to Recent Speculation

27 May 2025 13:45

RNS Number : 2692K
British American Tobacco PLC
27 May 2025
 

 

This announcement contains inside information

For immediate release

27 May 2025

British American Tobacco p.l.c.

Response to Recent Speculation

British American Tobacco p.l.c. (BAT) notes the recent speculation relating to a potential disposal of part of its shareholding in ITC Limited (ITC). BAT confirms that it is evaluating a possible disposal of a small part of BAT's shareholding in ITC by means of an on-market trade. There can be no certainty that any such transaction will proceed, nor can there be any certainty as to the terms of any potential transaction. A further announcement will be made if and when appropriate.

This announcement is being made on behalf of British American Tobacco p.l.c. by Caroline Ferland, Company Secretary.

ENQUIRIES

 

Press Office

+44 (0) 20 7845 2888 (24 hours) | @BATPress

Investor Relations

Victoria Buxton

IR_team@bat.com

 

 

NOTES TO EDITORS

Further information

This announcement contains inside information in relation to British American Tobacco p.l.c. for the purposes of Article 7 of the Market Abuse Regulation.

The securities referred to herein will not be, and have not been, registered under the United States Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

About BAT

BAT is a leading global multi-category consumer goods business. Underpinned by world-leading science and R&D, our purpose is to create A Better Tomorrow™ by Building a Smokeless World where, ultimately, cigarettes have become a thing of the past. BAT's purpose is backed by Omni™, an evidence-based manifesto for change which captures its commitment and progress.

BAT employs more than 48,000 people and, in 2024, generated revenue of £25.9bn, with an adjusted profit from operations of £11.9bn.

BAT's aim is to have 50 million adult consumers of its Smokeless products by 2030 and generate 50% of its revenue from Smokeless products by 2035. BAT's portfolio is made up of a growing range of nicotine and smokeless tobacco products which include its Vapour brand Vuse; Heated Product brand glo; and Velo, its Modern Oral (nicotine pouch) brand. After only a decade of investment in these products, the Group has delivered New Category revenue of £3.4bn in 2024, with strong progress in profitability. BAT's portfolio reflects our commitment to meeting the evolving and varied preferences of today's adult consumers.

BAT is also reducing the use of natural resources, improving livelihoods, and delivering on its climate goals to be Net Zero across its value chain by 2050. BAT received a Triple A rating from CDP in 2024 for its disclosures on Climate Change, Water Security, and Forests, showcasing its commitment to environmental transparency and action.

Forward-looking statements

This release contains certain forward-looking statements, including "forward-looking" statements made within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "believe," "anticipate," "could," "may," "would," "should," "intend," "plan," "potential," "predict," "will," "expect," "estimate," "project," "positioned," "strategy," "outlook", "target" and similar expressions. These include statements regarding our customer target ambition, New Categories revenue targets and our ESG targets.

All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in this release are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated. A review of the reasons why actual results and developments may differ materially from the expectations disclosed or implied within forward-looking statements can be found by referring to the information contained under the headings "Cautionary Statement" and "Group Principal Risks " in the 2024 Annual Report and Form 20-F of British American Tobacco p.l.c. (BAT). 

Additional information concerning these and other factors can be found in BAT's filings with the U.S. Securities and Exchange Commission ("SEC"), including the Annual Report on Form 20-F and Current Reports on Form 6-K, which may be obtained free of charge at the SEC's website, http://www.sec.gov and BAT's Annual Reports, which may be obtained free of charge from the BAT website www.bat.com.

Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser. The forward-looking statements reflect knowledge and information available at the date of preparation of this release and BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
SPCUBUURVKUVUAR
Date   Source Headline
4th Dec 202311:30 amRNSTotal Voting Rights
4th Dec 20239:24 amRNSDirectorate Change
24th Nov 20232:30 pmRNSDirector/PDMR Shareholding
13th Nov 20233:00 pmRNSDirector/PDMR Shareholding
13th Nov 20232:15 pmRNSDirector/PDMR Shareholding
8th Nov 20239:55 amRNSDirector/PDMR Shareholding
8th Nov 20239:50 amRNSDirector/PDMR Shareholding
8th Nov 20239:45 amRNSDirector/PDMR Shareholding
2nd Nov 20231:15 pmRNSDirector/PDMR Shareholding
2nd Nov 20237:00 amRNSBAT Appoints Chief Financial Officer
1st Nov 202312:10 pmRNSTotal Voting Rights
13th Oct 20237:00 amRNSBAT Appoints Chief People Officer
5th Oct 20231:00 pmRNSDirector/PDMR Shareholding
5th Oct 20237:00 amRNSDirectorate Change
2nd Oct 20231:40 pmRNSTotal Voting Rights
26th Sep 20232:40 pmRNSDirector/PDMR Shareholding
18th Sep 20237:00 amRNSBranch Register: Dividend Finalisation Information
14th Sep 20239:00 amRNSRussia business update - sale completed
12th Sep 20233:05 pmRNSDirector/PDMR Shareholding
7th Sep 20231:15 pmRNSDirector/PDMR Shareholding
7th Sep 20237:00 amRNSRussia business update – agreement signed
1st Sep 202310:30 amRNSTotal Voting Rights
24th Aug 20233:40 pmRNSDirector/PDMR Shareholding
22nd Aug 20234:50 pmRNSDirector/PDMR Shareholding
22nd Aug 20233:50 pmRNSDirector/PDMR Shareholding
22nd Aug 202312:25 pmRNSDirector/PDMR Shareholding
22nd Aug 202312:20 pmRNSDirector/PDMR Shareholding
22nd Aug 202312:15 pmRNSDirector/PDMR Shareholding
22nd Aug 20237:00 amRNSCompany Secretary Change
14th Aug 20234:53 pmRNSTender Offer Pricing
14th Aug 202311:30 amRNSResult of Tender Offer
3rd Aug 20233:30 pmRNSDirector/PDMR Shareholding
3rd Aug 202310:20 amRNSPublication of Supplementary Prospectus
1st Aug 202311:38 amRNSPricing Notes Offering
1st Aug 202310:35 amRNSTotal Voting Rights
31st Jul 20231:26 pmRNSTender Offer
26th Jul 20237:00 amRNSHalf-year Report
6th Jul 20233:00 pmRNSDirector/PDMR Shareholding
4th Jul 20237:00 amRNSBranch Register: Dividend Finalisation Information
3rd Jul 20231:40 pmRNSBlock listing Interim Review
3rd Jul 20231:30 pmRNSTotal Voting Rights
20th Jun 202311:00 amRNSDirector/PDMR Shareholding
19th Jun 20237:00 amRNSManagement Board Changes
8th Jun 202312:45 pmRNSDirector/PDMR Shareholding
6th Jun 202310:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNS2023 First Half Pre-Close Trading Update
1st Jun 202311:00 amRNSTotal Voting Rights
31st May 202310:45 amRNSDirector/PDMR Shareholding
24th May 20234:35 pmRNSDirector/PDMR Shareholding
22nd May 20232:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.